In melanoma, glioma, hepatocellular carcinoma, urothelial carcinoma, and others, TERT promoter mutations have been found to define subsets of patients with adverse disease outcomes (Heidenreich and Kumar, 2017). This evidence concerns the gene TERT and central nervous system cancer.